Phase II study of cisplatin plus S-1 with bevacizumab as first-line therapy for stage III/IV nonsquamous non-small-cell lung cancer
Not Applicable
- Conditions
- non-small-cell lung cancer (nonsquamous cell lung cancer)
- Registration Number
- JPRN-UMIN000003487
- Lead Sponsor
- Gunma University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
squamous cell (adenosquamous cell) lung cancer; Patients with a history of serious drug allergy, hemoptysis, thrombosis, concomitant malignancy, central nervous system metastases, active infectious diseases or other serious medical problems;hemorrhagic diathesis or coagulopathy; therapeutic anticoagulation; regular use of aspirin (>325 mg per day), nonsteroidal antiinflammatory agents, or other agents known to inhibit platelet function;use of steroid or flucytosine;pregnancy ;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method overall survival, progression-free survival, time to treatment failure, safety